US HIV guidelines updated (October 2017): dropping “HIV-infected”
22 January 2018. Related: Guidelines.
Simon Collins, HIV i-Base
The main US HIV treatment guidelines (HHS) were updated in October 2017. [1]
All changes are highlight in yellow in the PDF version of the quidelines.
Main changes include:
- Person-first language. Removing the offensive term “HIV-infected” when referring to HIV positive people and adopting more affirmative person-based language throughout. This is a way of reducing stigma and showing respect for individuals who are living with HIV by focussing on the person instead of the disease. Although this might seem a small point to many health professionals, similar changes were adopted by BHIVA from 2012 and by EACS from 2013.
-
- The classifications for initial therapy have been changed from three options of recommended, alternative, and other to:
- Recommended for most people; and
- Recommended in certain situations.
- Integrase inhibitor-based regimens are now recommended as first therapy for most people with HIV.
- NNRTI and PI-based combinations are now only recommended in certain clinical situations.
- Longer-term safety data have clarified that TAF has less bone and kidney toxicity but TDF is associated with lower lipid levels.
- Updates have been made throughout the section with new safety and clinical trial data.
- Monotherapy with any single ARV should not be used due to increased risk of virologic failure and drug resistance.
- Dual therapy using lamivudine plus either dolutegravir or boosted darunavir is not recommended, but is an alternative requiring closer monitoring in people who are not able to use other NRTIs.
- Efavirenz is (finally) no longer banned during the first trimester of pregnancy.
- The classifications of ART regimens have been changed from Recommended, Alternative, and Other to:
(i) Recommended regimens for most people; and
(ii) Recommended regimens in certain situations. (Specific regimens are listed in Table 6 of the guidelines.)
- “Low-level viremia” was defined at <200 copies/mL.
- Several sections were restructured.
- The importance of maintaining HBV treatment in people with hepatitis B virus (HBV)/HIV coinfection was emphasised.
- Ibalizumab and fostemsavir are included as pipeline compounds for people with .
- Discussion of several studies using two-drug maintenance therapy.
- Clinical trial data involving investigational combinations are discussed.
Coinfection with HIV HBV and/or HCV
- Both sections have been updated to discuss recent reports regarding reactivation of hepatitis B virus (HBV) infection in persons with HBV/hepatitis C virus (HCV) coinfection after starting interferon-free HCV therapy.
- Individuals with chronic HBV infection should receive treatment for HBV with NRTIs that are active against both HIV and HBV before starting HCV therapy.
- For the HCV section, interactions between new HCV direct-acting agents and ARV drugs have been added to Table 12.
- The section on adherence has been revised to also include HIV care.
- The importance of doctors working with a multidisciplinary team to understand barriers to care.
- New evidence-based interventions and best practices to improve adherence are summarised.
- In people with adherence problems, dolutegravir and boosted darunavir are mentioned given their high genetic barriers to resistance.
Additional updates have been made to the following sections:
- The classifications for initial therapy have been changed from three options of recommended, alternative, and other to:
comment
i-Base presented research on the use of HIV positive compared to HIV infected at the IAS conference in 2010, [1]
This contributed to the changes in BHIVA guidelines from 2012 and EACS guidelines from 2013.
References
- DHHS guidelines for the use of antiretroviral agents in adults and adolescents living with HIV (October 2017).
https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/0 - Collins S et al. HIV positive vs HIV infected: reducing barriers to clinical research through use of appropriate and accurate language. AIDS 2010, Vienna. Abs THPE0516.
http://www.abstract-archive.org/Abstract/Share/3331
DHHS guidelines for the use of antiretroviral agents in adults and adolescents living with HIV (October 2017).
https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/0